Science. Applied to Life.™

Science is on your side to help you prevent bloodstream infections.

# Bloodstream infections: A critical issue for patients and healthcare facilities.

Every IV catheter poses potential for serious and costly complications, including bloodstream infections (BSIs) which are associated with significant increases in care and costs. They are more common than you think and, in some cases, they can be deadly.<sup>1</sup>



### Sources of infection. Taking a closer look at points of access.

While vascular catheters provide the advantage of prolonged venous access, they present a risk of infectious complications. In fact, 60% of all hospital-acquired bloodstream infections originate from some form of vascular access.<sup>4</sup> These infections can be acquired at the time of the initial insertion or anytime throughout the duration of the venous access, with the majority of infections happening after insertion.<sup>5</sup>



Factors to consider to help reduce the risk of BSIs.

In addition to the risk of extraluminal and intraluminal contamination, BSIs can be introduced anytime during patient care. That's why it's important to consider additional solutions that meet best practices and help reduce risk throughout the process.

Intraluminal protection 田 AF . 45 45 LAP TY 铅 铅 铅 铅 铅 招 串 铅 铅

Hand hygiene

Extraluminal protection

田

帝 带 带

Skin

preparation

#

Skin protection

出

## Best practices for helping prevent BSIs.

Many well-regarded organizations have studied how to help prevent bloodstream infections. Following established evidence-based standards and best practice guidelines can aid you in your mission to help protect patients from BSIs.



Organizations include: The Canadian Vascular Access Association (CVAA), The Centers for Disease Control and Prevention (CDC), Association for Professionals in Infection Control and Epidemiology (APIC), The Infusion Nurses Society (INS), Oncology Nursing Society (ONS), and The Society for Healthcare Epidemiology of America (SHEA).



3M solutions can play a role in supporting government and industry guidelines aimed at infection and transmission control. 3M does not make any claims that its products prevent or reduce the incidence of infection or the transmission of disease. For specific 3M products, please refer to the intended use.

# Where science meets best practices.

When it comes to reducing the risk of BSIs, adhering to best practice guidelines is simpler when you have access to the solutions that align with them. From hand hygiene to securement devices and more, 3M can help you deliver the best possible patient care.



#### Prepare: Hand hygiene

#### Clean hands. Protected patients.

<u>3M<sup>™</sup> Avagard<sup>™</sup> D Instant Hand Antiseptic (61% w/w</u> <u>ethyl alcohol) with Moisturizers</u> combats dry hands with cosmetic grade emollients to help prevent dryness, maintain skin integrity and in turn enhance hand hygiene compliance. Evidence shows that this uniquely moisturizing formula really works. In fact, clinical studies have shown that 3M<sup>™</sup> Avagard<sup>™</sup> D Instant Hand Antiseptic actually enhanced skin hydration.<sup>9</sup>









#### Protects

patients against microorganisms and helps reduce the risk of infection or reduce bacteria on skin to diminish the risk of surgical site infection.



## A few minutes of preparation can improve patient outcomes.

Using <u>3M<sup>™</sup> SoluPrep<sup>™</sup> Brand Skin Antiseptic</u> products is one way you can prepare skin and help reduce the risk of infection at IV sites. Available in multiple formulations and delivery formats, including wipes, swabs and applicators, 3M<sup>™</sup> SoluPrep<sup>™</sup> Brand products are designed for use on intact skin prior to medically invasive procedures to help protect patients against the risk of infection.



skin antiseptic authorized in Canada for professional healthcare use.<sup>11</sup>



#### Protect: Skin protection

## Make clinically-supported skin protection part of your protocols.

Adding <u>3M<sup>™</sup> Cavilon<sup>™</sup> No Sting Barrier Film</u> to catheter insertion and dressing changes provides a unique terpolymer barrier solution to help promote skin protection. Be confident knowing it's the only barrier film supported by vascular access-specific data.<sup>13-15</sup>

In a study with patients with Peripherally Inserted Central Catheter (PICC) lines:<sup>13</sup>

62%

of patients experienced skin complications when gauze or tape was applied.



of patients experienced skin complications with Cavilon No Sting Barrier Film applied before gauze and tape protocol.





#### Aligns to best practices

- CHG compatible<sup>16</sup>
  - Sterile wands and wipes
- Unique easy-to-open, peel-down packaging allows aseptic delivery to the area that will be covered by the adhesive dressing/device



### Effective yet gentle

- ▶ Waterproof barrier
- Breathable
- Fast-drying<sup>17</sup>
- ▶ Alcohol-free<sup>18</sup>
- Sting-free<sup>18</sup>



## Extraluminal protection

#### Antimicrobial protection. Innovative securement. All in one.

Extraluminal contamination, a potential cause of catheter-associated bloodstream infections (CABSIs), happens when bacteria on the surface of the skin move along the outside of the catheter and enter through the insertion site. To help reduce this risk, <u>3M™ Tegaderm™</u> <u>CHG Chlorhexidine Gluconate I.V. Securement</u> <u>Dressings</u> provide immediate and continuous antimicrobial protection to an IV site.



#### Infection reduction

3M<sup>™</sup> Tegaderm<sup>™</sup> CHG Dressings are cleared and clinically proven to reduce catheter-related bloodstream infections (CRBSI).<sup>19</sup>

#### 60% reduction of CRBSIs

in a randomized controlled trial (RCT) of 1,879 critically ill adult subjects with 4,163 catheters.<sup>20</sup>



#### Site visibility

Transparent dressing and gel pad enable early identification of potential complications at IV site and meet INS recommendation to assess the IV site and surrounding area by visual inspection.<sup>7</sup>



erm V. ment og BioPatch® Disk with CHG



#### **Catheter securement**

Designed to minimize catheter movement and dislodgement and meets the INS definition of an integrated securement device (ISD) or adhesive securement device (ASD).<sup>19</sup>



#### **Greater pull force**

Tegaderm<sup>™</sup> CHG I.V. Securement Dressing 1657 can withstand 7.90 lb pull force on average, which is an average 1.09 lb greater pull force vs. SorbaView<sup>®</sup> SHIELD + BIOPATCH<sup>®</sup> 7 days after application.<sup>21</sup>

#### Ease of use

Integrated CHG gel pad and dressing design ensures standardized, correct application.<sup>22</sup>



Important Safety Information for 3M<sup>™</sup> Tegaderm<sup>™</sup> CHG Dressings. Do not use 3M<sup>™</sup> Tegaderm<sup>™</sup> CHG Dressings on premature infants or infants younger than two months of age. Use of this product on premature infants may result in hypersensitivity reactions or necrosis of the skin. The safety and effectiveness of 3M<sup>™</sup> Tegaderm<sup>™</sup> CHG Dressings has not been established in children under 18 years of age. For full prescribing information, see the Instructions for Use (IFU). Rx only.

#### Manage: Intraluminal protection

### Small, yet mighty to help the fight against BSIs.

Intraluminal contamination occurs when bacteria migrate through the catheter post insertion, typically via contamination of the lumen through the catheter port. The family of <u>3M™ Curos™ Disinfecting</u> <u>Port Protectors</u> contain isopropyl alcohol and twist onto ports for effective passive disinfection and protection to all IV access points.

Can be dispensed as individual caps or on strips<sup>\*</sup> that can be hung from IV poles for easy access and greater compliance. 'Varies by product.

**Save valuable time** with fast 1-minute disinfection that eliminates the need for "scrub the hub" protocols.

Brightly coloured to help visually verify that IV access points are covered at a glance and disinfection compliance can be easily and reliably measured.

#### Antimicrobial protection

3M<sup>™</sup> Curos<sup>™</sup> Disinfecting Port Protectors achieved



#### 99.99% reduction in six microbes commonly

associated with CLABSI (*in vitro*).<sup>23,24</sup>

Effective disinfection of needleless connectors and male luers on peripheral lines has been associated with a significant decrease in peripheral line-associated bloodstream infections (PLABSI).<sup>25</sup>

#### **1-minute disinfection**



## Cap contains

isopropyl alcohol (IPA) which bathes the surface of the IV access point and disinfects in 1 minute.<sup>26</sup>

#### Long lasting protection

Protects IV access points for up to 7 days if not removed. Passive disinfection removes human technique variance, providing consistent disinfection every time.<sup>26</sup>



#### Stays securely in place

Twists on easily and stays in place on commonly used IV access points — meeting INS standards for add-on devices. The Luer-lock design works with a wide range of open female luers.



# Education and training to stay ahead of the curve.

The clinical resources and education provided by 3M are designed to support you in each of the following areas, with a focus on your unique needs and challenges.





Identify

Identify the areas where you have the biggest opportunity to drive impact at your facility.

Learn

Learn about industry best practices, clinical evidence, and new ways to improve outcomes.



Improve

Improve or implement new work processes and protocols through a variety of tools and approaches.



Maintain

Maintain the progress you've made and continue to keep staff educated and engaged.

#### **3M** solutions

We understand every journey toward zero complications is unique. That's why our program includes customized assessment tools that:

- Empower you to drive compliance
- Streamline the auditing process
- Provide customized guidance and feedback
- Help define success

#### **Tools include:**

- IV Care and Maintenance
- Temperature Management
- Perioperative Care
- Sterilization Monitoring





- Siempos I, Kopterides P, Tsangaris I, Dimopoulou I, Armaganidis A. Impact of catheter-related bloodstream infections on the mortality of critically ill patients: A meta-analysis. Crit Care Med. 2009;37(7):2283-2289.
- 2. Laupland K, Lee H, Gregson D, Manns B. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect. 2006;63(2):124-32
- 3. Mermel L. Short-term Peripheral Venous Catheter-Related Bloodstream Infections: A Systematic Review. Clin Infect Dis. 2017:65(10):1757-1762.
- Scheithauer S, Lewalter K, Schröder J, et al. Reduction of central venous line-associated bloodstream infection rates by using a chlorhexidinecontaining dressing. *Infection*. 2014;42(1):155-159.
- Association for Professionals in Infection Control and Epidemiology, Inc. APIC Implementation Guide: Guide to Preventing Central Line-Associated Bloodstream Infections, 2015. https://apic.org/Resource\_/TinyMceFileManager/2015/APIC\_CLABSI\_WEB.pdf.
- 6. https://www.cdc.gov/handhygiene/providers/guideline.html
- 7. Gorski L, Hadaway L, Hagle ME, et al. Infusion Therapy Standards of Practice, 8th Edition. J Infus Nurs. 2021;44 (suppl 1):S1-S224. doi:10.1097/ NAN.000000000000396. Refer to the document to view verbatim, comprehensive standards and practice recommendations.
- Rupp ME, Cavalieri J, Delaney K, Lundgren K, Stammers L, Beach S. Prospective, randomized, controlled trial assessing the clinical performance of a transparent chlorhexidine gel pad intravascular catheter dressing. Poster presented at 18th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA); April 2008; Orlando, FL.
- 9. 3M data on file. LIMS 7780.
- 10. 3M data on file.
- 11. Health Canada Drug Product Database. Accessed January 1, 2017.
- 12. Based on 3M<sup>™</sup> SoluPrep<sup>™</sup> Brand sales data.
- 13. George M, Ujwala P, Guduri, V, Smith G. Use of a barrier film (3M<sup>™</sup> Cavilon<sup>™</sup> No Sting Barrier Film) to reduce local skin complications around peripherally inserted central catheter lines: A randomised prospective controlled study. *WCET Journal*. 2016; 36(4):8-13.
- 14. Pivkina A, Gusarov V, Blot S, et al. Effect of an acrylic terpolymer barrier film beneath transparent catheter dressings on skin integrity, risk of dressing disruption, catheter colonisation and infection. Intensive Crit Care Nurs. 2018; 46: 17-23.
- 15. Chen Y-H, Hsieh H-L, Shih W-M. Applying skin barrier film for skin tear management in patients with central venous catheterization. Adv Skin Wound Care. 2020; 33(11): 582-586.
- 16. 3M data on file. EM-05-005732 and EM-05-002049.
- 17. 3M data on file. EM-05-001563, EM-05-289804 (dry time).
- 18. Campbell K, Woodbury M, Whittle H, Labate T, Hoskin A. A clinical evaluation of 3M<sup>™</sup> Cavilon<sup>™</sup> No Sting Barrier Film. Ostomy Wound Management. 2000;46(1):24-30.
- U.S. Food and Drug Administration, Department of Health & Human Services. 3M<sup>™</sup> Tegaderm<sup>™</sup> CHG Chlorhexidine Gluconate I.V. Securement Dressing 510(k) K153410 approval letter, May 15, 2017. Retrieved September 1, 2021 from https://www.accessdata.fda.gov/cdrh\_docs/pdf15/ K153410.pdf
- 20. Timsit JF, Mimoz O, Mourvillier B, et al. Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. *Am J Respir Crit Care Med*. 2012;186(12):1272-1278.
- 21. 3M data on file. EM-05-014359.
- 22. Kohan C, Boyce J. A Different Experience with Two Different Chlorhexidine Gluconate Dressings for Use on Central Venous Devices. Am J Infect Control. 2013;41(6):S142–S143.
- 23. Data reflects in vitro findings on 3M<sup>™</sup> Curos<sup>™</sup> Disinfecting Port Protectors.
- Weiner L, Webb A, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014, Infect Control Hosp Epidemiol 2016;1–14.
- 25. Duncan M, Warden P, Bernatchez B, Morse D. A Bundled Approach to Decrease Primary Bloodstream Infections Related to Peripheral Intravenous Catheters. 2018, Journal of the Association of Vascular Access, 23(1), 15–22.
- 26. 3M data on file. CLAIM-SHEET-US-05-263340.

#### **Ordering information**

Prepare			
Hand Hygiene			
I	3M <sup>™</sup> Avagard <sup>™</sup> D Instant Hand Antiseptic		
	Personal size	9221C	88 mL
	Pump bottle	9222C	500 mL
Skin Preparation			
	3M <sup>™</sup> SoluPrep <sup>™</sup> QD Swab, Small Swab, Clear, 0.5% w/v CHG/70% v/v IPA	102.02	1.6 mL
Month Space 12 Contraction of A	3M <sup>™</sup> SoluPrep <sup>™</sup> Swab, Small Swab, Clear, 2% w/v CHG/70% v/v IPA	102.03	1.6 mL
	3M <sup>™</sup> SoluPrep <sup>™</sup> AQ Swab, Small Swab, Clear (Alcohol Free), 2% w/v CHG	102.07	1.6 mL
And State and St	3M <sup>™</sup> SoluPrep <sup>™</sup> Swab, Large Swab, Clear, 2% w/v CHG/70% v/v IPA	102.08	5.2 mL
CM CARACTER CONTRACTOR CONTRACTON	3M <sup>™</sup> SoluPrep <sup>™</sup> Swab, Large Swab, Tinted, 2% w/v CHG/70% v/v IPA	102.09	5.2 mL
Protect			
Skin protection			
	3M <sup>™</sup> Cavilon <sup>™</sup> No Sting Barrier Film		
	Wand	3343E	1 mL
	Wipe	3344E	1 mL
Secure			
Extraluminal p	rotection		
	3M <sup>™</sup> Tegaderm <sup>™</sup> CHG Chlorhexidine Gluconate I.V. Securement Dressing	1657R	CHG pad: 1 ⅔ in x 1 ½ in 3 cm x 4 cm Dressing: 3½ in x 4½ in 8,5 cm x 11,5 cm
	3M <sup>™</sup> Tegaderm <sup>™</sup> CHG Chlorhexidine Gluconate I.V. Securement Dressing	1659R	CHG pad: 1% in x 2 <sup>3</sup> /4 in 3  cm x 7 cm Dressing: 4  in x 6% in 10  cm x 15,5 cm
	3M <sup>™</sup> Tegaderm <sup>™</sup> CHG Chlorhexidine Gluconate I.V. Securement Dressing	1660R	CHG pad: 4/5 in x 4/5 in 2 cm x 2 cm Dressing: 2% in x 3% in 7 cm x 8.5 cm

CHG pad: 1<sup>1</sup>/2 in x 1<sup>3</sup>/8 in 3 cm x 4 cm 3M<sup>™</sup> PICC/CVC Securement Device + Tegaderm<sup>™</sup> CHG 1877R-Dressing: 3½ in x 4½ in Chlorhexidine Gluconate I.V. 2100 Securement Dressing 8,5 cm x 11,5 cm CHG pad: 1 1/2 in x 2⁴/5 in 3 cm x 7 cm 3M<sup>™</sup> PICC/CVC Securement 1879R-Device + Tegaderm<sup>™</sup> CHG Chlorhexidine Gluconate I.V. 2100 Dressing: 4 in x 61/% in Securement Dressing 10 cm x 15,5 cm 3M<sup>™</sup> Tegaderm<sup>™</sup> 3¾ in x 2 ¾ in 8,5 cm x 7 cm Antimicrobial I.V. Advanced 9132 Securement Dressing Manage 3M<sup>™</sup> Curos<sup>™</sup> Disinfecting CFF1-Caps for Needleless Individuals 270R Connectors 3M<sup>™</sup> Curos<sup>™</sup> Disinfecting CFF10-Strips Caps for Needleless 250R (10 count) Connectors LUL 3M<sup>™</sup> Curos Tips<sup>™</sup> Disinfecting CM5-Strips Cap for Male Luers 200R (5 count) 3M<sup>™</sup> Curos<sup>™</sup> Stopper CSA1-Individuals Disinfecting Cap for Open 270R Female Luers 3M<sup>™</sup> Curos<sup>™</sup> Stopper CSA5-Strips Disinfecting Cap for Open 250R (5 count) Female Luers 3M<sup>™</sup> Curos<sup>™</sup> Disinfecting CTG1-Caps for Tego® Hemodialysis Individuals 270R Connectors

**Extraluminal protection** 



Available in Canada from

#### Medical Solutions Division 3M Canada Company 300 Tartan Drive London, Ontario N5V 4M9 Canada 1-800-364-3577 3M.ca

**3M Company** 2510 Conway Ave. St. Paul, MN 55144 USA 1-800-228-3957

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product Instructions For Use prior to application.

© 2022 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. Used under license in Canada. All other marks are property of their respective owners. 2202-23103-EN